Triomics, a startup that builds AI tools for oncology teams, announced a $22 million Series B funding round in May 2026, led by Battery Ventures. Returning investors Nexus Venture Partners, Lightspeed, and Y Combinator also participated.
Founded in 2021, Triomics develops an AI-powered platform that helps oncologists and administrative staff automate data-heavy tasks, including clinical trial matching, appointment preparation, and tumor report submissions to government registries — a legal requirement for cancer centers. The company previously raised a $15 million Series A in mid-2024.
The platform’s core challenge is the sheer volume of patient data in oncology. Co-founder Sarim Khan told TechCrunch that the startup has encountered medical records running to thousands of pages, combining physician notes, imaging and pathology reports, and faxed documents. As oncology treatments have improved and patients live longer, those records have grown more complex, placing a heavier burden on clinical staff.
Triomics addresses this by generating verifiable patient summaries that surface key information directly inside tools clinicians already use, reducing the time spent on appointment prep and, by extension, freeing up more time for patient care. Khan noted that institutions such as Memorial Sloan Kettering and Yale Cancer Center use the platform because its models are trained specifically on oncology data, rather than relying on general-purpose AI.
The startup competes with AI medical scribe tools like Abridge and Microsoft’s Nuance in the patient chart summarization space. Despite that competition, Triomics reported a fourfold increase in enterprise customers over the past year, alongside a tenfold increase in annualized recurring revenue.
The new funding is expected to support continued platform expansion as the company scales its presence across cancer centers.
Source: TechCrunch